Featured image for “Phonak Launches Audéo Sphere Infinio and a New Range of AI-Powered Hearing Aids”
Aug. 05, 2024

Phonak Launches Audéo Sphere Infinio and a New Range of AI-Powered Hearing Aids

HHTM
STAFA, SWITZERLAND — Phonak, a Sonova brand, has announced the launch of a new family of hearing aids based on the innovative Infinio platform, including the Audéo Sphere Infinio. According to the announcement, it represents the world’s first hearing aid powered by a dedicated real-time AI chip designed for speech-from-noise separation. Addressing the persistent challenge of speech understanding in background
Featured image for “Sudden Hearing Loss: An Urgent Medical Concern”
Aug. 02, 2024

Sudden Hearing Loss: An Urgent Medical Concern

HHTM
Humans connect through communication, and hearing is a vital component of this process. Hearing loss, often associated with aging, can also be caused by genetics, ototoxicity, poor listening habits, ear disease, and other factors. It is frequently referred to as the invisible disease since it happens gradually and is not immediately noticeable until its effects become profound. However, sudden hearing
Featured image for “HearUSA Continues Expansion: New Hearing Center of the Future Opens in San Marcos, Texas”
Aug. 02, 2024

HearUSA Continues Expansion: New Hearing Center of the Future Opens in San Marcos, Texas

HHTM
PALM BEACH GARDENS, FLORIDA — Leading hearing care retailer HearUSA today announced the opening of a new state-of-the-art Hearing Center of the Future in the Springtown area of San Marcos, Texas, at 199 Springtown Way, Unit 12. The opening is part of HearUSA’s initiative to expand access to Simply Excellent Hearing Care through the latest prescription and over-the-counter (OTC) hearing
Featured image for “CQ Partners Announces Olympian Chaunté Lowe as Reconnect ’25 Keynote Speaker”
Aug. 02, 2024

CQ Partners Announces Olympian Chaunté Lowe as Reconnect ’25 Keynote Speaker

HHTM
CHADDS FORD, PENNSYLVANIA – CQ Partners has announced that Olympian and cancer survivor Chaunté Lowe will deliver the keynote address at the industry event, Reconnect ’25. Lowe will kick off Reconnect “with her positive, can-do attitude, empowering attendees throughout the event”. Reconnect ’25 will take place from February 27 to March 2, 2025, at the Omni Amelia Island Resort in
Featured image for “Sound Pharmaceuticals Completes Phase 3 Trial of SPI-1005 for the Treatment of Meniere’s Disease”
Jul. 31, 2024

Sound Pharmaceuticals Completes Phase 3 Trial of SPI-1005 for the Treatment of Meniere’s Disease

HHTM
SEATTLE, WASHINGTON — Sound Pharmaceuticals has announced the completion of the Phase 3 clinical trial for SPI-1005, a novel anti-inflammatory treatment for Meniere’s Disease (STOPMD-3). SPI-1005, an oral capsule taken twice daily, is the only potential therapeutic to show significant improvement in hearing loss and tinnitus in Meniere’s Disease patients, as demonstrated in two previous studies. The STOPMD-3 study enrolled
Featured image for “NALscribe AR: Enhancing Communication with Spatially-Aware Live Captions on Apple Vision Pro”
Jul. 31, 2024

NALscribe AR: Enhancing Communication with Spatially-Aware Live Captions on Apple Vision Pro

HHTM
Individuals with hearing loss often face significant challenges in understanding speech, especially in group conversations or noisy environments. These difficulties can lead to social isolation, withdrawal from activities, and reduced workplace participation. To address these issues, the National Acoustic Laboratories (NAL) is leveraging Apple Vision Pro’s mixed reality technology to enhance hearing health and communication accessibility. Introducing NALscribe AR, a
Featured image for “Concha Labs Unveils New Concha Sol™ Over-the-Counter Hearing Aids”
Jul. 30, 2024

Concha Labs Unveils New Concha Sol™ Over-the-Counter Hearing Aids

HHTM
SAN FRANCISCO, CALIFORNIA – Concha Labs has announced the launch of their FDA-cleared Concha Sol™ Hearing Aids, an over-the-counter (OTC) solution offering personalized hearing profiles that users can set up from their iPhones without any appointments. Priced at $1,299 per pair, these hearing aids aim to address the common frustrations of inconvenience, high cost, and poor sound personalization experienced by
Featured image for “Amplifon Boosts Revenues and Profitability in First Half of 2024, Continues Expansion in Key Markets”
Jul. 30, 2024

Amplifon Boosts Revenues and Profitability in First Half of 2024, Continues Expansion in Key Markets

HHTM
MILAN, ITALY — Amplifon S.p.A. has reported robust financial results for the first half of 2024, demonstrating significant growth in revenues and profitability. The company achieved consolidated revenues of €1.177 billion (approximately $1.28 billion USD), marking an 8% increase at constant exchange rates and a 5.7% increase at current exchange rates compared to the first half of 2023. This growth
Featured image for “New Collaboration Between Oticon and Henry Ford Health Aims to Improve Hearing Aid Outcomes”
Jul. 30, 2024

New Collaboration Between Oticon and Henry Ford Health Aims to Improve Hearing Aid Outcomes

HHTM
COPENHAGEN, DENMARK – Oticon A/S has launched a clinical research partnership with the Division of Audiology at Detroit, Michigan-based Henry Ford Health, one of the leading integrated and academic healthcare systems in the United States. The collaboration aims to generate valuable insights into post-fitting outcomes and hearing aid user experiences. The Oticon Clinical Research Team will work with Henry Ford
Featured image for “Macrophage Depletion Shows Promise in Preventing Chemotherapy-Induced Hearing Loss”
Jul. 30, 2024

Macrophage Depletion Shows Promise in Preventing Chemotherapy-Induced Hearing Loss

HHTM
Researchers have made significant progress in understanding how to reduce the harmful side effects of cisplatin, a common chemotherapy drug. Cisplatin is known for its effectiveness against various cancers but also for its severe side effects, especially hearing loss (ototoxicity) and kidney damage (nephrotoxicity). A recent study, led by a team from the National Institutes of Health (NIH) and other